| Name | Title | Contact Details |
|---|
Le groupe international Ondura est spécialisé dans les solutions détanchéité pour les bâtiments et regroupe des entreprises leaders dans leurs domaines : Onduline (toiture légère pour les toits en pente), CB (écrans de protection pour façades et de sous-toiture pour toits inclinés) et Alwitra (systèmes détanchéité hautes performances pour les toits plats). Il dispose de 13 usines en France, Allemagne, Pologne, Espagne, Russie, États-Unis, Malaisie, Brésil et Turquie. Il réalise un chiffre daffaires consolidé de 350 M€ dans plus de 100 pays et emploie 2000 personnes de 34 nationalités différentes.
Oakbridge Insurance is a prominent independent insurance and risk management agency with over 100 years of experience. Founded with a mission to enhance the insurance industry through community-focused service, Oakbridge combines the flexibility of an independent agency with the resources of a larger brokerage. As of 2023, it operates under Audax Private Equity, providing a range of commercial and personal insurance solutions. The company specializes in commercial property and casualty insurance, employee benefits, surety bonds, personal property and casualty insurance, and risk management services. Oakbridge operates through a partnership model, having expanded from four founding agencies to 13 partner firms by 2022, employing 280 people. The agency fosters a collaborative culture, emphasizing trust and long-term relationships with clients. In 2022, Oakbridge was recognized as a Top 100 Property/Casualty Agency by *Insurance Journal*, highlighting its strong position in the industry.
WE ARE A DESIGN COMPANY. Allovus is a woman-owned equal opportunity employer committed to fostering an inclusive and creative environment. Our employees produce meaningful work, create strong community connections, and inspire delight in our clients. Studio Our skilled and collaborative Design Studio team provides beautiful, elegant, and functional solutions for our clients. No matter the creative challenge, our intentionally small and agile team operates as a one-stop design shop. Custom Solutions Deliverable based teams, managed for you. In todays world, many of our clients are looking for ways to augment their own teams with creative talent in different ways outside the typical individual contractor approach. Our ability to build, nurture, and employ teams of people is one of our strongest attributes as an organization. Were excited to provide a model to our clients which allows you to retain a world-class team, while meeting the compliance standards of your organization, all while delivering amazing designs on time and on budget. Search We specialize in permanent placement using a holistic, qualitative approach to make the perfect match.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.